Related Experiment Video

Updated: Apr 6, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.2K

Opportunities for Nano-Formulations in Type 2 Diabetes Mellitus Treatments

Jaison Jeevanandam, Michael K Danquah, Sujan Debnath

  • 1Department of Chemical Engineering, Faculty of Engineering and Science, Curtin University CDT 250, 98009, Miri, Sarawak, Malaysia.

Current Pharmaceutical Biotechnology
|July 28, 2015
PubMed

Insights

This review explores nano-formulations for type 2 diabetes mellitus treatment. Nanoparticles offer unique properties for drug delivery and may reverse insulin resistance, presenting new therapeutic avenues.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Endocrinology

Background:

  • Type 2 diabetes mellitus (T2DM) is a prevalent global health concern, often linked to lifestyle factors.
  • Conventional T2DM treatments are primarily curative and symptom-driven.
  • There is a need for therapeutic strategies targeting the underlying cellular and molecular mechanisms of T2DM.

Purpose of the Study:

  • To review the application of nano-formulations in T2DM treatment.
  • To discuss the potential of nanomedicine in reversing insulin resistance.
  • To highlight novel therapeutic opportunities using nanoparticles for T2DM management.

Main Methods:

  • Literature review of current research on nanoparticles in diabetes treatment.
  • Analysis of nanoparticle characteristics (size, shape) and their impact on drug delivery.
  • Exploration of nanomedicine's role in addressing insulin resistance.

Main Results:

  • Nanoparticles possess unique biophysical properties suitable for drug delivery and manifestation.
  • Nanoparticles offer potential for targeted drug delivery and enhanced therapeutic efficacy in T2DM.
  • Emerging evidence suggests nanomedicine can play a role in reversing insulin resistance.

Conclusions:

  • Nano-formulations represent a promising frontier for T2DM treatment.
  • Nanoparticles can be engineered to improve drug delivery and potentially reverse key pathological mechanisms of T2DM.
  • Further research into nanomedicine holds significant potential for advancing T2DM therapy.

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.9K
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.8K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
965
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.1K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
961
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.6K